Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat and Everolimus in Metastatic Renal Cell Carcinoma
NCT01582009Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Mar 2010
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in renal cell carcinoma (RCC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Progression-free Survival at 3 years and Number of Participants With Clinical Response at 3 years. Started Mar 2010; status: terminated.
02
Drugs
panobinostat
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01582009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01582009.